<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585091</url>
  </required_header>
  <id_info>
    <org_study_id>00011909</org_study_id>
    <secondary_id>IRB# 00011909</secondary_id>
    <nct_id>NCT00585091</nct_id>
  </id_info>
  <brief_title>The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment</brief_title>
  <official_title>The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is now strong evidence from clinical trials that carvedilol therapy in heart failure is&#xD;
      superior to therapy with metoprolol. Not only does carvedilol have superior effects on lipid&#xD;
      profiles, insulin sensitivity, renal blood flow, and reversal of pathologic remodeling but&#xD;
      also its use is associated with fewer deaths compared to metoprolol. These facts make it&#xD;
      important to carefully define how metoprolol and carvedilol are pharmacologically different.&#xD;
      One potential difference is α1-AR antagonism. If we demonstrate that these α1-AR effects are&#xD;
      preserved with chronic therapy, then α1-AR blockade may have an important role in carvedilol&#xD;
      favorably altering the natural history of heart failure. On the other hand, if we demonstrate&#xD;
      that tolerance to the α1-AR blockade effect of carvedilol decreases with time, then it would&#xD;
      be unlikely that this pharmacologic property contributes to the efficacy of carvedilol. In&#xD;
      such a case other pharmacologic properties, such as antioxidant activity, would appear to be&#xD;
      important. These results will help guide future studies into CHF and AR blockade.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to determine if tolerance to α1-AR blockade develops with the chronic administration of carvedilol in heart failure patients.</measure>
    <time_frame>Oct 2003-Aug 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.</measure>
    <time_frame>Oct 2003-Aug 2008</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phenylephrine</intervention_name>
    <description>All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of 18 to 85 years&#xD;
&#xD;
          2. Symptomatic heart failure, NYHA class I to III&#xD;
&#xD;
          3. Left ventricular ejection fraction &lt; 0.40&#xD;
&#xD;
          4. Give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. active myocarditis&#xD;
&#xD;
          2. congenital heart disease&#xD;
&#xD;
          3. uncorrected, hemodynamically significant stenotic valvular disease&#xD;
&#xD;
          4. hypertrophic cardiomyopathy&#xD;
&#xD;
          5. Asthma or other obstructive airway diseases requiring bronchodilators&#xD;
&#xD;
          6. Heart rate &lt; 60 beats/min, supine systolic blood pressure &lt; 85 mm Hg, supine diastolic&#xD;
             blood pressure &gt; 90 mm Hg&#xD;
&#xD;
          7. Uncontrolled Hypertension (Systolic BP &gt;140 mmHg, Diastolic BP &gt; 90 mmHg).&#xD;
&#xD;
          8. Sick sinus syndrome, Mobitz type 2 second degree AV block or third degree AV block&#xD;
             unless controlled with an artificial implantable pacemaker&#xD;
&#xD;
          9. NYHA functional class IV symptoms&#xD;
&#xD;
         10. Treatment with an excluded medication (see Excluded Medications below)&#xD;
&#xD;
         11. Myocardial infarction or coronary artery intervention (CABG or angioplasty) within&#xD;
             three months&#xD;
&#xD;
         12. Unstable angina pectoris&#xD;
&#xD;
         13. Presence of any progressive systemic disease that would be expected to impact the&#xD;
             patient's outcome over the time course of the study&#xD;
&#xD;
         14. Uncorrected endocrine disorders including primary aldosteronism, pheochromocytoma,&#xD;
             hyperthyroidism, hypothyroidism, brittle type 1 diabetes mellitus&#xD;
&#xD;
         15. Evidence of significant renal disease (serum creatinine &gt; 2.5 mg/dl), or hepatic&#xD;
             disease (transaminase level &gt; three fold higher than laboratory normal)&#xD;
&#xD;
         16. Symptomatic peripheral vascular disease&#xD;
&#xD;
         17. Inability or unwillingness to cooperate with study or give written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Munger, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Pharmacotherapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Van Tassell BW, Rondina MT, Huggins F, Gilbert EM, Munger MA. Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction. Am Heart J. 2008 Aug;156(2):315-21. doi: 10.1016/j.ahj.2008.04.004. Epub 2008 Jun 20.</citation>
    <PMID>18657662</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>edward gilbert</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

